Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim for PBPC Mobilization in Multiple Myeloma
NCT00067639Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2003
- Primary completion
- Apr 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Efficacy of pegfilgrastim in mobilizing progenitor cells. Started Dec 2003; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00067639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00067639.